Details
Category: Volume 07 Issue 06 June 2019
Hits: 1016

Title: Presence and Positivity of High Risk HPV with Increase in the Severity of Cytological Abnormalities Detected on Pap Smear: A Study of 40 Cases

Authors: Prof. Dr Meena Mittal, Prof. Dr C.V. Kulkarni, Dr Sachin Sharma, Prof. Dr Ashok Panchonia, Dr Ankesh Kumar Jain, Dr Priya Jain

 DOI: https://dx.doi.org/10.18535/jmscr/v7i6.117

Abstract

Introduction

Cervical cancer ranked second among most commonly diagnosed cancer and in less developed countries it is third leading cause of cancer related death among females[1,2,3]  It is estimated that each year, 527,000 new case occur and 275, 000 deaths. Globally, 15% of all cancer in females is cervical cancer.[2,4]. In India about 20% of all cancer related deaths is due to cervical cancer in women and is the number one cause of death in middle aged Indian women.[5]

Cancer cervix is a multifactorial disease. Human Papilloma virus (HPV) infection is the most important risk factor.[6] It has been shown recently that cervical cancer is strongly associated with the presence of high risk or oncogenic Human Papilloma virus (HPV) types (up to 100%). [7,8] The HPV virus is belongs to the family Papovaviridae, genus papillomavirus.[9,10] having double stranded, circular DNA. The HPV subtypes which specifically affect the anogenital tract are 16, 18, 31, 33, 35, 39, 45,51, 52, 56, 58, 66 and 69. [11]. It is important to understand genomic organization of the virus to understand the oncogenic process induced by HPV that leads to development of cervical dysplasia. Significant regions include the early (E), the late (L),[12] and the long control region (LCR).[13]  E6 binds with p53 tumor suppressor  gene, causes its degeneration while E7 binds retinoblastoma gene products.[14] thus,  inactivation of p53 and pRB  leads to cell cycle progression[15] and immortalization of normal cervical cells, so it is the expression of viral oncogenes E6 /E7 which is  prerequisite for progression toward malignancy and maintenance of the cancerous phenotype [16,17].As the severity of the lesion increases levels of E6/E7 also rises.[18,19] E6 and E7 transcripts could be useful as markers of disease progression.[18]

Thus, the objective of the study is to evaluate the expression of E6/E7 mRNA of HPV types 16, 18, 31, 33, 35, 39 ,45 , 51, 52, 56 , 58 , 59 , 68  and  82 (which together accounts for 95% of cervical cancer)[4] in cervical samples using flow cytometry and its correlation with epithelial cell abnormalities detected by pap smear

References

  1. Lindsey A. Torre; Freddie Bray; Rebecca L. Siegel; Jacques Ferlay; JoannieLortet-Tieulent; AhmedinJemal. Global Cancer Statistics, 2012. CA CANCER J CLIN 2015;65:87–108: 99-100.
  2. Bojgua S; Kldiashvili E. Liquid Based Cytology Cervical Cancer Screening Program – Georgian Experience. Arch Can Res. 2016, 4: 3.
  3. Ekane, G.E.H et al. (2015) Pap smear Screening, the Way Forward for Prevention of Cervical Cancer? A Community Based Study in the Buea Health District, Cameroon. Open Journal of Obstetrics and Gynecology, 5, 226-233.
  4. Gakidou E; Nordhagen S; Obermeyer Z (2008) Coverage of cervical cancer screening in 57 countries: Low average levels and large inequalities. Plos Med 5(6): e132. Doi:10.1371/journal. Pmed.0050132.
  5. Basu Partha; Chowdhury Debjani. Cervical cancer screening & HPV vaccination: a comprehensive approach to cervical cancer control. Indian J Med Res 130, September 2009, pp 241-246.
  6. Schiffman M, Castle PE, Jeronim J, Rodrigue AC, Wacholde S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890–907. [PubMed]
  7. Van den Brule AJC, Walboomers JMM, du Maine M, Kenemans P, Meijer CJLM. Difference in prevalence of human papillomavirus genotypes in cytomorphologically normal cervical smears is associated with a history of cervical intraepithelial neoplasia. Int J Cancer 1991;48: 404-8.
  8. Resnick RM, Comelissen MTE, Wright DK, Eichinger GH, Fox HS, ter Schegget J, et al. Detection and typing of human papilloma virus in archival cervical cancer specimens by DNA amplification with consensus primers. J Natl Cancer Inst 1990;82:1477-84.
  9. Kaufman RH, Adam E, Vonka V. Human papillomavirus infection and cervical carcinoma. Clin Obstet Gynecol 2000;43:363–80.
  10. Harrison’s principles of internal medicine. 14th Edition on CD-ROM.New York: McGraw-Hill, 1999
  11. Khan S, Jaffer NN, Khan MN, Rai MA, Shafiq M, Ali A, Pervez S, Khan N,Aziz A, Ali SH: Human papillomavirus subtype 16 is common inPakistaniwomen with cervical carcinoma. Int J Infect Dis 2007, 11:313-317.
  12. Gagnon D, Joubert S, Senechal H, Fradet-Turcotte A, Torre S, Archambault J: Proteasomal degradation of the papillomavirus E2 protein is inhibited by overexpression of bromodomain containing protein 4. J Virol 2009,83:4127-4139.
  13. Muller Schiffmann A, Beckmann J, Steger G: The E6 protein of the cutaneous human papillomavirus type 8 can stimulate the viral earlyand late promoters by distinct mechanisms. J Virol 2006, 80:8718-8728
  14. Porass C, Bennett C, Safaeian M, Coseo S, Rodriguez AC, Gonzaález P,Hutchinson M, Jimenez S, Sherman ME, Wacholder S, Solomon D, DoornLeen-Jan V, Bougelet C, Quint W, Schiffman M, Herrero R, Hildeshein A: Determinants of Seropositivity among HPV16/18DNA positive young women. BMC Infect Dis 2010, 10:238.
  15. Molecular biologists for Oncologists: Edited by: Yarnold JR, Stratton MR, Mcm Millan TJ. Chapman and Hall; , 2 1996:83-88.
  16. Fehrmann F, Laimins LA. Human papillomaviruses targeting differentiating epithelial cells for malignant transformation. Oncogene 2003;22:5201 – 7.
  17. Boulet G, Horvath C, Vanden Broeck D, et al. Human papillomavirus:E6 and E7 oncogenes. Int J Biochem Cell Biol 2007;39:2006 – 11.
  18. Cattani P, Zannoni GF, Ricci C, et al. Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix. J ClinMicrobiol 2009;47(12):3895–3901
  19. Argyri E, Tsimplaki E, Daskalopoulou D, et al. E6/E7 mRNA expression of high-risk HPV types in 849 Greek women. Anticancer Res 2013;33(9):4007–4011
  20. Patel M.M., Pandya A.N., Modi J. — Cervical pap smear study and its utility in cancer screening, to specify the strategy for cervical cancer control. National Journal of Community Medicine; vol 2, issue1, 2011.
  21. Ghaith J.E., Rizwana B.S. — Rate of Opportunistic Pap smear Screening and Patterns of Epithelial Cell Abnormalities in Pap Smears in Ajman, United Arab Emirates. Sultan Qaboos Univ Med J; 12(4): 473–478, 2012.
  22. Khan MS, Raja FY, Ishfaq G, Tahir F, Subhan F,Kazi BM et al. Pap smear Screening for Precancerous conditions of the cervical cancers. Pak J. Med. Res.
  23. Edelman M, Fox A. Cervical Papanicolau smear abnormalities in inner Bronx adolescents: Prevalence, progression, and immune modifiers. Cancer (cancer cytopathology). 1999;87:184-9.
  24. New therapeutic strategies for human papillomavirus related anogenital lesions in HIV patients: highly active antiretroviral therapy andHPV vaccines]. Fusté P, Santamaría X, Carreras R.Med Clin (Barc). 2008 Jun 7;131(1):30-4. Review. Spanish.PMID:18582422
  25. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. InsingaRP, Liaw KL, Johnson LG, Madeleine MM.Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1611-22. doi: 10.1158/1055-9965.EPI-07-2922. Review PMID:18628412 Free PMC Article
  26. WHO/ICO HPV information centre. Human papillomavirus and related cancers. Summary Report Update.June 22,2010
  27. Cernescu EC, Anton G, Ruţă S, Cernescu C. The effectiveness of cytological rescreening in the reduction of false negative/positive Pap reports. Roum Arch MicrobiolImmunol 2013; 72(2):93–104
  28. Poomtavorn Y, Himakhun W, Suwannarurk K, Thaweekul Y, Maireang K. Cytohistologic discrepancy of high-grade squamous intraepithelial lesions in Papanicolaou smears. Asian Pac J Cancer Prev 2013;14(1):599–602
  29. Lie AK, Kristensen G. Human papillomavirus E6/E7 mRNA testing as a predictive marker for cervical carcinoma. Expert Rev Mol-Diagn 2008;8(4):405–415
  30. C. Rijkaart, D. A. M. Heideman, V. M. H. Coupe, A. A. T. P. Brink, R. H. M. Verheijen, H. Skomedal et al High-Risk Human Papillomavirus (hrHPV) E6/E7 mRNA Testing by PreTect HPV-Proofer for Detection of Cervical High-Grade Intraepithelial Neoplasia and Cancer among hrHPV DNA-Positive Women with Normal Cytology, Journal of Clinical Microbiology July 2012 ; Volume 50 (7) p. 2390–2396
  31. Nayar R; David C. Wilbur. The Bethesda System for Reporting Cervical Cytology, Third Edition, springer. ISBN 978-3-319-11073-8 ISBN 978-3-319-11074-5, DOI 10.1007/978-3-319-11074-5
  32. Ayre J. E; Dakin, E. Cervical Cytology Tests in Cancer Diagnosis: Glycerine Technique of Mailing, Canad. M. A. J. 54:489-491 (May) 1946
  33. ALINDA D. VARNAI, MAGDOLNA BOLLMANN, AGNES BANKFALVI,NORBERT SPEICH, CHRISTOPH SCHMITT, HARALD GRIEFINGHOLT et al Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: Diagnostic and prognostic implications ONCOLOGY REPORTS 19 2008 p. 457-465.
  34. Ozer Birge. Detection of HPV E6/E7 Mrna Using Nuclisens Easyq HPV™ in AbnormalCytology Specimens. J Gynecol Women’s Health. 2018: 10(3): 555794. DOI: 10.19080/JGWH.2018.10.555794.
  35. Boer DMA, Jordanova ES, Kenter GG, Peters AA, Corver WE, et al. High human papillomavirus oncogene mRNA expression and not viral DNA load is associated with poor prognosis in cervical cancer patients. Clin Cancer Res 2007,13(1): 132-138
  36. Halfon P, Benmoura D, Agostini A, Khiri H, Martineau A, et al. Relevance of HPV mRNA detection in a population of ASCUS plus women using the NucliSENS EasyQ HPV assay. J Clin Virol 2010, 47(2): 177- 181.
  37. Sorbye SW, Fismen S, Gutteberg TJ, Mortensen ES HPV mRNA test in women with minor cervical lesions: experience of the University Hospital of North Norway. J Virol Methods 2010,169(1): 219-222.
  38. Rashmirani Senapati1, Bhagyalaxmi Nayak, Shantanu Kumar Kar and Bhagirathi Dwibedi HPV Genotypes distribution in Indian women with and without cervical carcinoma: Implication for HPV vaccination program in Odisha, Eastern India BMC Infectious Diseases (2017) 17:30DOI 10.1186/s12879-016-2136-4.

Corresponding Author

Dr Priya Jain